A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms ELIGANT
- Sponsors Astellas Pharma
- 25 Sep 2018 Planned End Date changed from 1 Jan 2020 to 1 Nov 2019.
- 25 Sep 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Nov 2019.
- 31 Aug 2018 Biomarkers information updated